| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL1RAP |
| Uniprot No | Q9NPH3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-356aa |
| 氨基酸序列 | SERCDDWGLDTMRQIQVFEDEPARIKCPLFEHFLKFNYSTAHSAGLTLIW YWTRQDRDLEEPINFRLPENRISKEKDVLWFRPTLLNDTGNYTCMLRNTT YCSKVAFPLEVVQKDSCFNSPMKLPVHKLYIEYGIQRITCPNVDGYFPSS VKPTITWYMGCYKIQNFNNVIPEGMNLSFLIALISNNGNYTCVVTYPENG RTFHLTRTLTVKVVGSPKNAVPPVIHSPNDHVVYEKEPGEELLIPCTVYF SFLMDSRNEVWWTIDGKKPDDITIDVTINESISHSRTEDETRTQILSIKK VTSEDLKRSYVCHARSAKGEVAKAAKVKQKGNRCGQ |
| 预测分子量 | 40 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3篇关于IL1RAP重组蛋白的模拟参考文献(内容为示例性质，建议通过PubMed等数据库获取真实文献)：
---
1. **标题**: *Structural insights into IL1RAP interaction with interleukin-1 family cytokines*
**作者**: Smith A, et al.
**摘要**: 通过X射线晶体学解析IL1RAP重组蛋白与IL-1β/IL-33的复合物结构，揭示其作为共受体调控炎症信号通路的分子机制。
---
2. **标题**: *IL1RAP as a therapeutic target in myeloid malignancies*
**作者**: Johnson R, et al.
**摘要**: 研究IL1RAP重组蛋白在白血病干细胞中的高表达，证明其抗体靶向治疗可抑制癌细胞增殖并增强化疗敏感性。
---
3. **标题**: *Recombinant IL1RAP-Fc fusion protein attenuates inflammatory arthritis in murine models*
**作者**: Chen L, et al.
**摘要**: 开发IL1RAP胞外域-Fc融合蛋白，通过阻断IL-1家族细胞因子信号显著减轻小鼠类风湿性关节炎症状。
---
4. **标题**: *IL1RAP isoforms in immune signaling: Functional characterization using recombinant proteins*
**作者**: Müller S, et al.
**摘要**: 对比两种IL1RAP重组蛋白异构体(可溶型与膜结合型)，揭示其在NF-κB和MAPK通路中的差异调控作用。
---
注：以上文献信息为示例，实际研究需查阅具体论文(可通过PubMed搜索关键词：IL1RAP, recombinant protein, therapeutic target)。
**Background of IL1RAP Recombinant Protein**
Interleukin-1 receptor accessory protein (IL1RAP) is a critical co-receptor in the interleukin-1 (IL-1) signaling pathway, which plays a central role in regulating inflammatory and immune responses. As a member of the IL-1 receptor family, IL1RAP lacks intrinsic signaling capacity but is essential for forming functional receptor complexes with IL-1R1 or IL-1R2. Upon binding of IL-1 ligands (e.g., IL-1α, IL-1β), IL1RAP stabilizes the receptor-ligand interaction and facilitates downstream signaling via MyD88-dependent pathways, leading to NF-κB activation and pro-inflammatory cytokine production. Dysregulation of IL-1 signaling is implicated in autoimmune diseases, chronic inflammation, and cancer, making IL1RAP a potential therapeutic target.
Recombinant IL1RAP proteins are engineered using expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified, bioactive forms of the protein. These recombinant variants often include specific domains, such as the extracellular region required for ligand-receptor binding, and may carry tags (e.g., Fc or His tags) for ease of purification and detection. They serve as valuable tools for studying IL-1 signaling mechanisms, screening inhibitors, or developing therapeutic strategies. For instance, IL1RAP-targeting antibodies or decoy receptors derived from recombinant IL1RAP are being explored to block pathogenic IL-1 signaling in conditions like rheumatoid arthritis or inflammatory bowel disease.
Additionally, IL1RAP has gained attention in oncology due to its overexpression on certain cancer cells and involvement in tumor microenvironment modulation. Recombinant IL1RAP proteins enable researchers to dissect its role in cancer progression or evaluate its potential as a biomarker. Overall, IL1RAP recombinant proteins bridge basic research and clinical applications, offering insights into inflammation-driven diseases and opportunities for targeted interventions.
×
